Company Profile
AN2 Therapeutics Stock Price, News & Analysis
- Ticker:
- ANTX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.08 USD (+4.11%)
Close
Last updated: August 6, 2026
147M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ANTX closed up 4.11% at $6.08. No new same-company headline was identified in the current news window.
Company overview
Boron-Based Drug Development
AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning infectious disease and hematology.
Epetraborole in M. abscessus
Epetraborole is an oral investigational therapy being studied in an investigator-initiated Phase 2 trial for *Mycobacterium abscessus* lung disease. The study is intended to establish clinical proof of concept and inform a potential pivotal program.
Epetraborole in Polycythemia Vera
AN2 is separately preparing a Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera, extending the candidate from infectious disease into hematology.
Chagas Disease Program
AN2-502998 is an oral candidate for chronic Chagas disease. The program includes first-in-human clinical evaluation and translational efficacy work in non-human primates.
Oncology Discovery Pipeline
AN2 has declared a boron-containing ENPP1 inhibitor for solid tumors and is also researching PI3Kα and other difficult-to-drug targets in oncology and bone disorders.
Future catalysts
Phase 1 and non-human-primate data for AN2-502998 in the second quarter of 2026.
Initiation of the epetraborole Phase 2 study in polycythemia vera in the third quarter of 2026.
Initial periodic data from the polycythemia vera study as early as the fourth quarter of 2026, with additional readouts through 2027.
Recent news
- 01
- 02
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Source: AN2 Therapeutics
- 03
- 04
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Source: AN2 Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AN2 Therapeutics (ANTX)?
AN2 Therapeutics (ANTX) most recently closed at 6.08 USD, a +4.11% move versus the previous session.
What is the market cap of AN2 Therapeutics (ANTX)?
AN2 Therapeutics currently has a market capitalization of 147M USD on BioPharmSignal.
What does AN2 Therapeutics do?
Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning infectious disease and hematology. Epetraborole in M. abscessus Epetraborole is an oral investigational therapy being studied in an investigator-initiated Phase 2 trial for *Mycobacterium abscessus* lung disease....
On which exchange is ANTX stock listed?
AN2 Therapeutics (ANTX) is associated with NASDAQ, United States, Biopharma.
What is proof-of-concept?
Epetraborole in Polycythemia Vera AN2 is separately preparing a Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent polycythemia vera, extending the candidate from infectious disease into hematology.
Which conditions is AN2 Therapeutics targeting with proof-of-concept?
AN2 Therapeutics is associated with oncology, hematology based on its company overview and current catalyst commentary.
How does AN2 Therapeutics describe recent progress with proof-of-concept?
Phase 1 and non-human-primate data for AN2-502998 in the second quarter of 2026. Initiation of the epetraborole Phase 2 study in polycythemia vera in the third quarter of 2026. Initial periodic data from the polycythemia vera study as early as the fourth quarter of 2026, with additional readouts through 2027.
What is Boron-Based?
Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning infectious disease and hematology.